ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,505.00
      0.00%
      US Tech 100
      19,217.60
      1.09%
      Dow Jones
      40,287.53
      0.00%
      Brent Oil
      81.205
      -1.31%
      Bitcoin
      67,682.96
      -0.70%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Cartesian Therapeutics Inc (RNAC) Quote

      Cartesian Therapeutics Inc

      Cartesian Therapeutics Inc (RNAC)

      NASDAQ
      16.16
      -0.53
      (-3.18%)
      Closed July 19 4:00PM
      Delayed by 15 minutes
      16.16
      0.00
      ( 0.00% )
      Pre Market: 4:29AM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      16.16
      Bid
      16.00
      Ask
      18.58
      Volume
      11
      0.00 Day's Range 0.00
      11.665 52 Week Range 42.60
      Market Cap
      287.584M
      Previous Close
      16.16
      Open
      -
      Last Trade
      1
      @
      16.4
      Last Trade Time
      08:38:48
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      148,988
      Shares Outstanding
      17,796,053
      Dividend Yield
      -
      PE Ratio
      -1.31
      Earnings Per Share (EPS)
      -12.35
      Revenue
      26M
      Net Profit
      -219.71M

      About Cartesian Therapeutics Inc

      Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL... Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.selectabio.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Cartesian Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RNAC. The last closing price for Cartesian Therapeutics was $16.16. Over the last year, Cartesian Therapeutics shares have traded in a share price range of $ 11.665 to $ 42.60.

      Cartesian Therapeutics currently has 17,796,053 shares outstanding. The market capitalization of Cartesian Therapeutics is $287.58 million. Cartesian Therapeutics has a price to earnings ratio (PE ratio) of -1.31.

      RNAC Latest News

      More News

      Cartesian Therapeutics Announces New Employment Inducement Grants

      GAITHERSBURG, Md., July 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...

      July 08 2024
      GlobeNewswire Inc.

      Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

      GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for...

      July 02 2024
      GlobeNewswire Inc.

      Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

      GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for...

      July 02 2024
      GlobeNewswire Inc.

      Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

      Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at...

      July 02 2024
      GlobeNewswire Inc.

      Cartesian Therapeutics Announces New Employment Inducement Grant

      GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...

      June 06 2024
      GlobeNewswire Inc.

      Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

      GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for...

      May 22 2024
      GlobeNewswire Inc.

      Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

      GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...

      May 13 2024
      GlobeNewswire Inc.

      Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

      Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for mid-2024 On track to dose first patient in Phase...

      May 08 2024
      GlobeNewswire Inc.

      Cartesian Therapeutics Announces New Employment Inducement Grants

      Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the...

      May 06 2024
      Business Wire

      Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

      Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that recently reported...

      April 22 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-1.22-7.0195627157717.3820.9916.0614168517.34166394CS
      4-6.2-27.728085867622.3629.6515.3126623617.48151945CS
      12-5.58-25.666973321121.7441.8715.3114898821.50475318CS
      26-7.873-32.759122872724.03341.8711.66535716420.03749399CS
      52-8.035-33.209340772924.19542.611.66554457123.24199771CS
      156-8.035-33.209340772924.19542.611.66554457123.24199771CS
      260-8.035-33.209340772924.19542.611.66554457123.24199771CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MIRAMIRA Pharmaceuticals Inc
      $ 1.01
      (46.63%)
      		9.2M
      SERVServe Robotics Inc
      $ 10.21
      (35.23%)
      		23.9M
      RRRichtech Robotics Inc
      $ 1.88
      (27.89%)
      		13.25M
      NCPLNetcapital Inc
      $ 0.1325
      (27.40%)
      		35.37M
      DBVTDBV Technologies SA
      $ 1.01
      (20.24%)
      		342.03k
      HUBCWHub Cyber Security Ltd
      $ 0.0121
      (-47.39%)
      		1.67k
      XCURExicure Inc
      $ 0.3948
      (-26.22%)
      		401.45k
      SNTGSentage Holdings Inc
      $ 2.0205
      (-18.53%)
      		26.87k
      PIRSPieris Pharmaceuticals Inc
      $ 6.00
      (-17.24%)
      		10
      BCBPBCB Bancorp Inc
      $ 10.20
      (-16.53%)
      		628
      NCPLNetcapital Inc
      $ 0.1325
      (27.40%)
      		35.37M
      SERVServe Robotics Inc
      $ 10.21
      (35.23%)
      		23.9M
      RRRichtech Robotics Inc
      $ 1.88
      (27.89%)
      		13.25M
      MAXNMaxeon Solar Technologies Ltd
      $ 0.229
      (6.22%)
      		9.41M
      MIRAMIRA Pharmaceuticals Inc
      $ 1.01
      (46.63%)
      		9.2M

      Discussion

      View Full Feed
      Double DD Double DD 4 minutes ago
      Buy the blood!!!! Igpk baby,, give me all your shares and move on!!! Weeee igpk
      IGPK
      RealDutch RealDutch 4 minutes ago
      He said he is an ITUP shareholder. Not MyCow. By proxy. I assume that means he is representing someone else?

      But it's a good point. Anyone receiving vertical shares through ITUP/IREEM has to pay $0.01 per vertical share. Which also means they are on record at MyCow. Not sure if he has
      ITUP
      S3lfMade S3lfMade 5 minutes ago
      Pre clinical.. P1 is still 1+ year away
      MIRA
      train21 train21 5 minutes ago
      FINRA may not approve
      they are shooting for the moon and watch how many shares magically appear when the share price is in dollars ?????
      I have no faith zero faith in these CEOS
      CEOS
      splintered sunlight splintered sunlight 5 minutes ago
      Why don't you take out the .15's/16/17/18/19/20's and so on if you are so confident?
      BBUZ
      TappyS TappyS 5 minutes ago
      Agreed! I really hope the quarterly revenues exceed projections; that the Blackwell chip and the platforms are selling like pancakes, and their inventory is all sold - before even being manufactured!
      NVDA
      meitze meitze 5 minutes ago
      It's been a month since the pr about Nexboards 3rd pilot production run and we're out of mid July. So, that run should be done. No more over promising and under delivering. We need an update. When (date) is NFPA 286 test? Etc. Let's go!
      XERI
      Filterthenoise Filterthenoise 5 minutes ago
      Bring the goods $RNVA
      RNVA
      Filterthenoise Filterthenoise 5 minutes ago
      Bring the goods $RNVA
      RNVA
      StayHumble StayHumble 6 minutes ago
      $HCMCs amended complaint presents an even Stronger Case @healthiercmc

      https://static1.squarespace.com/static/58a1d7b8893fc0b6d3e47931/t/6436df8d94fa09523deadf45/1681317773824/2023-04-12_HCMC_v_PM_Appellate_Decision.pdf


      @InsidePMI annotated Newly Minted mockup f
      HCMC PM
      al44 al44 6 minutes ago
      The Fracturing of the Democrat Party

      By Steve McCann

      The summer of 2024 will be remembered for two events that changed the political landscape of United States: the attempted assassination of Donald Trump and the fracturing of America’s oldest political party.
      Taur1112 Taur1112 6 minutes ago
      Biden out! Great start to 2025!!! Lfg moni
      MONI
      Filterthenoise Filterthenoise 6 minutes ago
      Approx. 4 weeks until Q2 fins are due fwiw?$RNVA
      RNVA
      Nemesis18 Nemesis18 6 minutes ago
      Not a fan then ?
      NWBO
      ExtremelyBullishZig ExtremelyBullishZig 6 minutes ago
      LOL...okay...pump us up George!
      AVXL
      splintered sunlight splintered sunlight 6 minutes ago
      Exactly

      Exactly my point!!!!!!
      BBUZ
      StayHumble StayHumble 7 minutes ago
      $HCMC says Protect. Enforce.Monetize.License🟩🟩🟩
      https://static1.squarespace.com/static/58a1d7b8893fc0b6d3e47931/t/63599cf2e6708456f8187f4c/1666817273168/HCMC_LDMicroOct2022.pdf
      HCMC
      splintered sunlight splintered sunlight 7 minutes ago
      LOL

      Completely clueless......
      BBUZ
      nicehit nicehit 8 minutes ago
      As always, there is a lot of talk, so it's the wait game! Hold on to your shares or your balls because one will get squeezed!
      NSAV
      uranium-pinto-beans uranium-pinto-beans 8 minutes ago
      gooooooooooood morning
      LandPro LandPro 8 minutes ago
      Obviously, this is another example that holding 💩 shares like this is a terrible game plan. Stupid simple. .004's soon, again.
      IGPK
      StayHumble StayHumble 8 minutes ago
      w0w NO R/S+MERGER AQUISITION 🟩ohBoy onDECKYowza!
      https://x.com/CorporateUbqu/status/1765510100628726105?s=20
      https://cdn.vox-cdn.com/uploads/chorus_asset/file/8687957/tenor.gif
      UBQU
      train21 train21 8 minutes ago
      MDA your right 24 million shares and after the R/S you got 500 shares don't see how this gets to 6 bucks a share in order to make a little money ??? and SCHWAB drags its feet on relisting a R/S SO Schwab people are going to lose money any way ????
      and the PILLOW GUY is broke ???
      INCT

      Your Recent History

      NASDAQ
      RNAC
      Cartesian Therapeutics
      EU
      4467T
      4467T
      XE
      H2A
      H2APEX Group SCA
      NYSE
      V
      Visa
      Delayed Upgrade Clock